Company Filing History:
Years Active: 2024
Title: Christine Kuettel: Innovator in Her2-Targeted Therapeutics
Introduction
Christine Kuettel is a prominent inventor based in Schlieren, Switzerland. She has made significant contributions to the field of biomedicine, particularly in the development of targeted therapies for cancer treatment. Her innovative work focuses on creating molecules that can effectively bind to specific antigens, enhancing the efficacy of cancer therapies.
Latest Patents
Christine holds a patent for "Agonistic CD28 antigen binding molecules targeting Her2." This invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28. The patent outlines methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same. This groundbreaking work has the potential to improve treatment outcomes for patients with Her2-positive cancers.
Career Highlights
Christine is currently employed at Hoffmann-La Roche Inc., a leading global healthcare company. Her role involves research and development in the field of biopharmaceuticals, where she applies her expertise to create innovative solutions for complex medical challenges. With her dedication and skill, she has established herself as a key player in her field.
Collaborations
Christine collaborates with esteemed colleagues, including Stephan Gasser and Thomas U. Hofer. Together, they work on advancing the understanding and application of targeted therapies, contributing to the ongoing evolution of cancer treatment.
Conclusion
Christine Kuettel's contributions to the field of biomedicine, particularly through her patent on Her2-targeted therapies, highlight her role as an influential inventor. Her work at Hoffmann-La Roche Inc. and collaborations with other experts underscore her commitment to advancing healthcare solutions.